{{Rsnum
|rsid=8004608
|Gene=MDGA2
|Chromosome=14
|position=47618211
|Orientation=plus
|GMAF=0.09642
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=MDGA2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 2.2 | 30.7 | 67.2
| JPT | 8.9 | 37.5 | 53.6
| YRI | 2.0 | 19.0 | 78.9
| ASW | 3.6 | 36.4 | 60.0
| CHB | 2.2 | 30.7 | 67.2
| CHD | 5.7 | 34.0 | 60.4
| GIH | 0.0 | 0.0 | 0.0
| LWK | 4.6 | 30.3 | 65.1
| MEX | 0.0 | 0.0 | 0.0
| MKK | 2.7 | 20.0 | 77.3
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs8004608
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.02, combined P value= 2.03E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470208
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8004608
|overall_frequency_n=11
|overall_frequency_d=128
|overall_frequency=0.0859375
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | Affy GenomeWide 6}}